Hereditary Thrombophilic Risk Factors and Venous Thromboembolism in Istanbul,Turkey: The Role in Different Clinical Manifestations of Venous Thromboembolism

Abstract

The aim of this study was to investigate the hereditary thrombophilic risk factors in patients with venous thromboembolism (VTE) and whether these risk factors play a different role in patients with isolated pulmonary embolism (PE) as compared with patients with deep vein thrombosis (DVT) and patients with PE + DVT. The protein C (PC), protein S, antithrombin activities, homocysteine levels, and factor V Leiden (FVL) G1691A and prothrombin G20210A mutations were evaluated in 191 patients with VTE and 191 controls. The prevalence of FVL and PC deficiency were higher in patients (P = .003 and P = .02, respectively). There was no significant difference for the other risk factors. The combination of thrombophilic risk factors was significantly higher in patients with DVT + PE as compared with patients with isolated PE or DVT (P = .04). In conclusion, the most important hereditary risk factors for VTE in this study were the FVL mutation and PC deficiency.

Keywords

factor V Leiden prothrombin 20210A natural anticoagulant pulmonary embolism deep vein thrombosis

References

Rosendaal FR Thrombosis in the young: epidemiology and risk factors: a focus on venous thrombosis. Thromb Haemost. 1997;78:1-6.

Jordan FLJ , Nandorff A. The familial tendency in thromboembolic disease . Acta Med Scand. 1956;156:267-275.

De Stefano V. , Finazzi G. , Mannucci PM Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood. 1996;87:3531-3544.

Tait RC , Walker ID , Perry DJ , et al. Prevalence of antithrombin deficiency in the healthy population . Br J Haematol. 1994;87:106-112.

Seligsohn U. , Lubetsky A. Genetic susceptibility to venous thrombosis . N Engl J Med. 2001;344:1222-1231.

Martinelli I. , Mannucci PM , De Stefano V. , et al. Different risk of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood. 1998;92:2353-2358.

De Stefano V. , Leone G. , Mastrangelo S. , et al. Clinical manifestations and management of inherited thrombophilia: retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost. 1994;72:352-358.

Dahlback B. , Carlsson M. , Svensson PJ Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc NaH Acad Sci USA . 1993;90:1004-1008.

Bertina RM , Koeleman BP , Koster T. , et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.

10.

Ridker PM , Hennekens CH , Lindpaintner K. , et al. Mutation in the gene coding for coagulation factor V and risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Engl J Med. 1995;332: 1912-1917.

11.

Eichinger S. , Pabinger I. , Stumpflen A. , et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden . Thromb Haemost . 1997;77: 624-628.

12.

Cattaneo M. , Chantarangkul V. , Taioli E. , et al. The G20210A mutation of the prothrombin gene in patients with previous first episodes of deep-vein thrombosis; prevalence and association with factor V G1691A, methylenetetrahydrofolate reductase C677T and plasma prothrombin levels. Thromb Res. 1999;93:1-8.

13.

Poort SR , Rosendaal FR , Reitsma PH , et al. A common genetic variation region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.

14.

Tosetto A. , Missiaglia E. , Frezzato M. , et al. The VITA project: prothrombin G20210A mutation and venous thromboembolism in the general population. Thromb Haemost. 1999;82:1395-1398.

15.

Souto JC , Coll I. , Llobet D. , et al. The prothrombin 20210A allele is the most prevalent genetic risk factor for venous thromboembolism in the Spanish population. Thromb Haemost. 1998;80:366-369.

16.

Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis . Thromb Haemost. 1999;81:165-176.

17.

De Stefano V. , Casorelli I. , Rossi E. , et al. Interaction between hyperhomocysteinemia and inherited thrombophilic factors in venous thromboembolism. Sem Thromb Haemost. 2000 ;26:305-311.

18.

Martinelli I. , Cattaneo M. , Panzeri D. , et al. Low prevalence of Factor V:Q506 in 41 patients with isolated pulmonary embolism. Thromb Haemost . 1997;77:440-443.

19.

Turkstra F. , Karemaker R. , Kuijer PM , et al. Is the prevalence of the factor V Leiden mutation in patients with pulmonary embolism and deep vein thrombosis really different? Thromb Haemost. 1999;81:345-348.

20.

Manten B. , Westendorp RG , Koster T. , et al. Risk factor profiles in patients with different clinical manifestations of venous thromboembolism. Thromb Haemost. 1996;76: 510-513.

21.

Margaglione M. , Brancaccio V. , De Lucia D. , et al. Inherited thrombophilic risk factors and venous thrombolism. Chest. 2000;118:1405-1411.

22.

Ubbink JB , Vermaak WHJ , Bissbork S. Rapid high performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatography. 1991 ; 565:441-446.

23.

Vester B. , Rasmussen K. High performance liquid chromatography method for rapid and accurate determination of homocysteine in plasma and serum. Eur J Clin Chem Clin Biochem. 1991;29:549-554.

24.

Hessner MJ , Luhm RA , Pearson SL , et al. Prevalence of prothrombin G20210A, factor V G1691A (Leiden), and methylenetetrahydrofolate reductase (MTHFR) C677T in seven different populations determined by multiplex allele-specific PCR. Thromb Haemost . 1999;81:733-738.

25.

Dzimiri N. , Meyer B. World distribution of factor V Leiden. Lancet. 1996;347:481-482.

26.

Pepe G. , Rickards O. , Vanegas OC , et al. Prevalence of factor V Leiden mutation in non- European populations. Thromb Haemost. 1997;77:329-331.

27.

Rees DC , Cox Cleeg JB World distribution of factor V Leiden. Lancet. 1995;346:1133-1134.

28.

Gürgey A. , Mesci L. The prevalence of factor V Leiden (1691 G-A) mutation in Turkey. Turk J Pediatr. 1997;39:313-315.

29.

Akar N. , Akar E. , Dalgin G. , et al. Frequency of factor V (1691 G-A) mutation in Turkish population . Thromb Haemost. 1997;78:1527-1529.

30.

Meyer G. , Emmerich J. , Helley D. , et al. Factors V Leiden and II 20210A in patients with symptomatic pulmonary embolism and deep vein thrombosis. Am J Med. 2001; 110:12-15.

31.

Nizankowska-Mogilnicka E. , Adamek L. , Grzanka P. , et al. Genetic polymorphisms associated with acute pulmonary embolism and deep venous thrombosis . Eur Respir J. 2003;21:25-30.

32.

Cogo A. , Bernardi E. , Prandoni P. , et al. Acquired risk factors for deep vein thrombosis in symptomatic patients. Arch Intern Med. 1994;154:164-168.

33.

Zeinali S. , Duca F. , Zarbakhsh B. , et al. Thrombophilic mutations in Iran. Thromb Haemost . 2000;83:351-352.

34.

Lin JS , Shen MC , Tsay W. The mutation at position 20210 in the 3'-untranslated region of the prothrombin gene is extremely rare in Taiwanese Chinese patients with venous thrombophilia . Thromb Haemost. 1998;80:343.

35.

Hillarp A. , Zoller B. , Svensson PJ , et al. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost. 1997;78:990-992.

36.

Cumming AM , Keeney S. , Salden A. , et al. The prothrombin gene G20210A variant: prevalence in a U.K. anticoagulant clinic population. Br J Haematol. 1997; 98:353-355.